Results 51 to 60 of about 35,907 (256)

BRCA germline mutation test for all woman with ovarian cancer?

BMC Cancer, 2019
Background Delivering widespread BRCA testing to patients with ovarian cancer has been suggested by several scientists, recommended by professional societies and solicited by patients organizations.
A. V. Paradiso, M. Digennaro, M. Patruno, S. De Summa, S. Tommasi, I. Berindan-Neagoe   +5 more
doaj   +1 more source

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer

Breast, 2022
Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients.
A. Viansone, B. Pellegrino, C. Omarini, M. Pistelli, D. Boggiani, A. Sikokis, V. Uliana, D. Zanoni, C. Tommasi, B. Bortesi, F. Bonatti, F. Piacentini, L. Cortesi, R. Camisa, P. Sgargi, M. Michiara, A. Musolino   +16 more
doaj   +1 more source

BRCA mutation carriers’ perception about benefits and risks associated with combined hormonal contraceptives use

, 2022
To evaluate the actual perceptions about combined hormonal contraceptives (CHCs) use in BRCA mutation carriers in comparison to women from the general population.Objective: To evaluate the actual perceptions about combined hormonal contraceptives (CHCs ...
Boggio Sola V., del Savio M. C., Melotti C., Facchinetti F., Barra F., Centurioni M. G., Grandi G., Varesco L., Toss A., Gustavino C., Monari F., Cortesi L.   +11 more
core   +1 more source

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients

Gynecologic Oncology Reports, 2020
To evaluate BRCA1/2 immunohistochemistry (IHC) as a screening test for germline BRCA1/2 in epithelial ovarian cancer (EOC), tumor tissue from 105 EOC patients who had germline BRCA mutations, including 9 BRCA1 mutations, 6 BRCA2 mutations and 90 no BRCA mutations, were studied. Paraffin-embedded tissue blocks were stained for BRCA1 and BRCA2.
Tarinee Manchana, Patou Tantbirojn, Natkrita Pohthipornthawat   +2 more
openaire   +3 more sources

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

Frontiers in Oncology, 2022
ObjectiveTo study the correlation between BRCA mutation status and the risk of adverse reactions in patients with ovarian cancer.MethodA real-world study was conducted at the largest gynecological oncology center in western China, the West China Second ...
Kemin Li, Kemin Li, Jing Zeng, Jing Zeng, Mengpei Zhang, Mengpei Zhang, Rutie Yin, Rutie Yin, Zhengyu Li, Zhengyu Li   +9 more
doaj   +1 more source

Expert consensus on population-based BRCA germline mutation screening in China (2024 edition) [PDF]

Zhongguo aizheng zazhi
Germline mutations in BRCA genes (including BRCA1/2) are the major risk factors for hereditary tumors including breast and ovarian cancer. Population based BRCA gene screening, particularly in high-risk individuals with a family history of cancer, can ...
China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

BRCA-deficient subtype signature identifies triple negative breast cancer patients with improved survival with anthracycline/taxane chemotherapy.

, 2016
(A) Proportion of BRCA-D tumors among TNBC tumors in different CMB categories. (B) Overall survival of TNBC patients by BRCA deficiency status in the TCGA cohort.
Vikram B. Wali (3396224), Lajos Pusztai (78763), Charles Li (3396221), Weiwei Shi (139867), Rosanna Lau (380895), Balázs Győrffy (110652), Richard P. Lifton (147862), Tingting Jiang (169999), Christos Hatzis (565382), Lőrinc S. Pongor (101774), William F. Symmans (3396218)   +10 more
core   +1 more source

Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans

Medicina, 2020
Background and Objectives: This study aimed to evaluate the effect of a BRCA mutation on survival and failure patterns, focusing on the risk of ipsilateral recurrence and contralateral breast cancer in patients.
Hakyoung Kim, Doo Ho Choi, Won Park
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source